Form D · Pharmaceuticals
Lumina Pharmaceuticals Inc.
Boston, MA · CIK 0002069952
Offering snapshot reported Jun 20, 2025 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- May 7, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 20, 2025 | Initial | $2,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-549406
Simple Agreement for Future Equity
Source: Form D, filed Jun 20, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Caravan | Director |
| Cara Ferreira | Director, Executive |
| Alma Gregory Sorensen | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1 Huntington Ave. #1802
Boston, MA, 02116
Phone: 617-420-1150
Boston, MA, 02116
Phone: 617-420-1150